NCT07016529
Diagnostic Study for Differentiating Functional From Organic Diseases in Patients With Lower GIT Symptoms
Not Yet Recruiting · Not specified · Sohag University · registry updated 2025-06-11
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The study is intended to find a new trusted, cost-effective biomarker for differentiating irritable bowel syndrome from inflammatory bowel disease to decrease the use of unnecessary invasive methods in patients with irritable bowel syndrome
Inclusion
- Adults (≥18 years) presenting with chronic lower gastrointestinal symptoms, such as diarrhea, abdominal pain, or altered bowel habits, for a duration exceeding 6 weeks.
- Patients with no prior diagnosis of IBD or IBS.
- Patients willing to provide informed consent and comply with study requirements.
- Those without recent use of immunosuppressants or anti-inflammatory medications that could affect biomarker levels
Exclusion
- Patients with a confirmed diagnosis of IBD and currently on treatment.
- Those with acute gastroenteritis, infectious colitis, or positive stool cultures for pathogens.
- Patients diagnosed with colorectal cancer, celiac disease, or other known organic GI disorders.
- Recent antibiotic, NSAID, or corticosteroid use within the past 4 weeks.
- Pregnant or lactating women.